Patents by Inventor Matteo Biagetti

Matteo Biagetti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS
    Publication number: 20240116947
    Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
    Type: Application
    Filed: July 14, 2021
    Publication date: April 11, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Daniele PALA, Daniela PIZZIRANI, Paolo BRUNO, Paolo RONCHI, Matteo BIAGETTI, Sara GUARIENTO, Claudio FIORELLI
  • PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS
    Publication number: 20240116948
    Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
    Type: Application
    Filed: December 20, 2021
    Publication date: April 11, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Daniele PALA, Daniela PIZZIRANI, Paolo BRUNO, Matteo BIAGETTI, Paolo RONCHI, Sara GUARIENTO, Barbara BERTANI, Donatella RESCIGNO
  • AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS
    Publication number: 20240025880
    Abstract: The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: November 26, 2021
    Publication date: January 25, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Claudio FIORELLI, Paolo BRUNO, Matteo BIAGETTI, Daniela PIZZIRANI, Daniele PALA, Paolo RONCHI, Sara GUARIENTO, Charles BAKER-GLENN, Hervé VAN DE POËL, Kim Louise HIRST
  • PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS
    Publication number: 20240018122
    Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
    Type: Application
    Filed: July 14, 2021
    Publication date: January 18, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Daniela PIZZIRANI, Matteo BIAGETTI, Paolo RONCHI, Paolo BRUNO, Sara GUARIENTO, Barbara BERTANI, Daniele PALA, Alessio BARILLI
  • PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS
    Publication number: 20240002371
    Abstract: The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are phthalazine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: November 26, 2021
    Publication date: January 4, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Claudio FIORELLI, Paolo BRUNO, Matteo BIAGETTI, Charles BAKER-GLENN, Hervè VAN DE POËL
  • (AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS
    Publication number: 20230416233
    Abstract: The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are (aza)quinoline 4-amines derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: November 26, 2021
    Publication date: December 28, 2023
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Claudio FIORELLI, Paolo BRUNO, Matteo BIAGETTI, Charles BAKER-GLENN, Hervè VAN DE POËL
  • PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS
    Publication number: 20230212169
    Abstract: The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3 (hereinafter P2X3 inhibitors); particularly the invention relates to compounds that are pyridopyrimidines derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: May 28, 2020
    Publication date: July 6, 2023
    Inventors: Paolo BRUNO, Matteo BIAGETTI, Claudio FIORELLI, Charles BAKER-GLENN, Hervè VAN DE POËL, Stephen David PENROSE, Roberta LANARO
  • AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS
    Publication number: 20230092892
    Abstract: The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: May 28, 2020
    Publication date: March 23, 2023
    Inventors: Paolo BRUNO, Matteo BIAGETTI, Claudio FIORELLI, Daniela PIZZIRANI, Daniele PALA, Paolo RONCHI, Charles BAKER-GLENN, Hervè VAN DE POËL, Kim Louise HIRST
  • PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS
    Publication number: 20220235060
    Abstract: The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3 (hereinafter P2X3 inhibitors); particularly the invention relates to compounds that are pyridopyrimidines derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: May 28, 2020
    Publication date: July 28, 2022
    Inventors: Paolo BRUNO, Matteo BIAGETTI, Claudio FIORELLI, Charles BAKER-GLENN, Hervè VAN DE POËL, Stephen David PENROSE, Roberta LANARO
  • AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS
    Publication number: 20220227749
    Abstract: The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: May 28, 2020
    Publication date: July 21, 2022
    Inventors: Paolo BRUNO, Matteo BIAGETTI, Claudio FIORELLI, Daniela PIZZIRANI, Daniele PALA, Paolo RONCHI, Charles BAKER-GLENN, Hervè VAN DE POËL, Kim Louise HIRST, Sara GUARIENTO
  • ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS
    Publication number: 20220175784
    Abstract: The invention relates to compounds of formula (I) inhibiting phosphoinositide 3-kinases (PI3K), to pharmaceutical compositions comprising them and therapeutic use thereof in the treatment of disorders associated with PI3K enzymes.
    Type: Application
    Filed: March 24, 2020
    Publication date: June 9, 2022
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Matteo BIAGETTI, Paolo RONCHI, Claudio FIORELLI, Paolo BRUNO
  • Pyrazole derivatives as phosphoinositide 3-kinases inhibitors
    Patent number: 10189844
    Abstract: Compounds of formula (I) defined herein are phosphoinositide 3-kinases (PI3K) inhibitors and are useful for the treatment of disorders associated with PI3K enzymes.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: January 29, 2019
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Matteo Biagetti, Anna Maria Capelli, Michele Retini
  • Chromene derivatives as phoshoinositide 3-kinases inhibitors
    Patent number: 9968604
    Abstract: Chromene compounds of formula (I), defined herein, inhibit phosphoinositide 3-kinases (PI3K) and are useful for the treatment of disorders associated with a PI3K enzyme mechanism, such as asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: May 15, 2018
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Anna Maria Capelli, Matteo Biagetti, Alessandro Accetta
  • Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors
    Patent number: 9745308
    Abstract: Compounds of formula (I) described herein inhibit phosphoinositide 3-kinases (PI3K) and useful for the treatment of disorders associated with PI3K enzymes.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: August 29, 2017
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Matteo Biagetti, Anna Maria Capelli, Matilde Guala
  • PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS
    Publication number: 20170226109
    Abstract: Compounds of formula (I) defined herein are phosphoinositide 3-kinases (PI3K) inhibitors and are useful for the treatment of disorders associated with PI3K enzymes.
    Type: Application
    Filed: January 31, 2017
    Publication date: August 10, 2017
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Matteo BIAGETTI, Anna Maria CAPELLI, Michele RETINI
  • Indolizine derivatives as phoshoinositide 3-kinases inhibitors
    Patent number: 9527869
    Abstract: Compounds of formula (I), defined herein, inhibit phosphoinositide 3-kinases (PI3K) and are useful for the treatment of disorders associated with PI3K enzymes.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: December 27, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Matteo Biagetti, Alessandro Accetta, Anna Maria Capelli, Matilde Guala, Michele Retini
  • CHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS
    Publication number: 20160303123
    Abstract: Chromene compounds of formula (I), defined herein, inhibit phosphoinositide 3-kinases (PI3K) and are useful for the treatment of disorders associated with a PI3K enzyme mechanism, such as asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis.
    Type: Application
    Filed: March 24, 2016
    Publication date: October 20, 2016
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Anna Maria CAPELLI, Matteo BIAGETTI, Alessandro ACCETTA
  • Isochromene derivatives as phoshoinositide 3-kinases inhibitors
    Patent number: 9321776
    Abstract: Compounds of formula (I) described herein are useful for inhibiting phosphoinositide 3-kinases (PI3K) and the treatment of disorders associated with PI3K enzymes.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: April 26, 2016
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Matteo Biagetti, Anna Maria Capelli, Alessandro Accetta, Laura Carzaniga
  • PYRIDAZINONE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS
    Publication number: 20160075710
    Abstract: Compounds of formula (I) described herein inhibit phosphoinositide 3-kinases (PI3K) and useful for the treatment of disorders associated with PI3K enzymes.
    Type: Application
    Filed: August 31, 2015
    Publication date: March 17, 2016
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Matteo BIAGETTI, Anna Maria Capelli, Matilde Guala
  • INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS
    Publication number: 20150361100
    Abstract: Compounds of formula (I), defined herein, inhibit phosphoinositide 3-kinases (PI3K) and are useful for the treatment of disorders associated with PI3K enzymes.
    Type: Application
    Filed: June 17, 2015
    Publication date: December 17, 2015
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Matteo BIAGETTI, Alessandro ACCETTA, Anna Maria CAPELLI, Matilde GUALA, Michele RETINI